"[Humira] has been on the market for over a decade now ...

... and those R&D investments were made back in the 1990s. As we've said here before, it's become increasingly clear that drug prices are no longer driven by development costs. With years and years of blockbuster sales and unjustifiable pricing, it is time for drug makers to step up and set affordable prescription drug prices."

— AHIP said in a Nov. 2 blog posting.